Literature DB >> 12427420

Thrombolytic therapy of pulmonary embolism: a meta-analysis.

Gabriel Thabut1, Dominique Thabut, Robert P Myers, Brigitte Bernard-Chabert, Rolana Marrash-Chahla, Hervé Mal, Michel Fournier.   

Abstract

OBJECTIVES: We sought to assess the efficacy and safety of thrombolytic therapy in patients with an acute pulmonary embolism (PE).
BACKGROUND: Thrombolytic therapy is approved for the treatment of acute PE; however, the safety and efficacy of this therapy remain debated.
METHODS: A meta-analysis of randomized, controlled trials comparing thrombolytic agents with intravenous heparin in patients with acute PE was performed. Trials were identified through a combined search of the MEDLINE, EMBASE, and Current Contents databases. Three outcome measures were assessed: 1) mortality, 2) recurrence of PE, and 3) major hemorrhage.
RESULTS: Nine trials including 461 patients were identified. Compared with intravenous heparin, thrombolytic therapy had no significant effect on mortality (relative risk [RR] 0.63, 95% confidence interval [CI] 0.32 to 1.23) or the recurrence of PE (RR 0.59, 95% CI 0.30 to 1.18), but was associated with an increased risk of major hemorrhage (RR 1.76, 95% CI 1.04 to 2.98). These results were homogeneous and largely unaffected by the formulation of thrombolytic agent, the clinical severity of PE, the extent of vascular obstruction determined radiologically, or the methodologic quality of the included trials.
CONCLUSIONS: Compared with intravenous heparin, thrombolytic therapy does not appear to have therapeutic benefit in unselected patients with acute PE, but it is associated with an increased risk of major hemorrhage. Given the small number of patients included in the randomized trials thus far, the negative results in terms of the efficacy outcomes should be interpreted with caution. Definitive evidence of the utility of thrombolytic therapy in this setting requires a large, randomized, controlled trial.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427420     DOI: 10.1016/s0735-1097(02)02381-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 2.  When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature.

Authors:  T Harris; S Meek
Journal:  Emerg Med J       Date:  2005-11       Impact factor: 2.740

Review 3.  Tenecteplase to treat pulmonary embolism in the emergency department.

Authors:  Jeffrey A Kline; Jackeline Hernandez-Nino; Alan E Jones
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

4.  Review of acute pulmonary embolism in a general hospital.

Authors:  Keiichi Ishida; Masahisa Masuda
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

5.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

6.  Systemic Full Dose, Half Dose, and Catheter Directed Thrombolysis for Pulmonary Embolism. When to Use and How to Choose?

Authors:  Mohsen Sharifi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-05

7.  tPA regulates pulmonary vascular activity through NMDA receptors.

Authors:  Taher Nassar; Khalil Bdeir; Serge Yarovoi; Rami Abu Fanne; Juan-Carlos Murciano; Steven Idell; Timothy Craig Allen; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

8.  Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin.

Authors:  Carlos Jerjes-Sánchez; Sergio Villarreal-Umaña; Alicia Ramírez-Rivera; Anabel Garcia-Sosa; Luis Miguel-Canseco; Tamara Archondo; Esteban Reyes; Angel Garza; Roberto Arriaga; Francisco Castillo; Omar Jasso; Hector Garcia; Martha Bermudez; Jose Maria Hernandez; Jorge Garcia; Pedro Martinez; Francisco Rangel; Jorge Gutierrez; Alfredo Comparan-Nuñez
Journal:  J Thromb Thrombolysis       Date:  2008-01-19       Impact factor: 2.300

9.  Aggressive management of pulmonary embolism.

Authors:  Nael Saad
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

10.  Outcome of thrombolysis for massive pulmonary embolism.

Authors:  E Aniteye; M Tettey; L Sereboe; F Edwin; D Kotei; A Doku; M Tamatey; K Enstuah-Mensah; I Delia; K Frimpong-Boateng
Journal:  Ghana Med J       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.